Are you bothered by Atopic Dermatitis? If so, this new Atopic Dermatitis Clinical Trial might be interesting for you.
Answer a few questions and see if you may be eligible for this Research Study testing an investigational treatment for patients with Atopic Dermatitis.
Purpose of the study
The purpose of this study is to compare the effects of the study drugs (an investigational drug called abrocitinib and dupilumab) to find out which is better for treating Atopic Dermatitis (Atopic Eczema) in adults who are also receiving medicated and non-medicated skin therapy.
If you enroll in this study, you will receive both tablets and injections. One will be the real study drug and the other one will be the placebo (no active ingredients).
Who may participate in this study?
You may qualify for this research study, if the following applies to you:
- · You are at least 18 years old
- You have moderate to severe Atopic Dermatitis
- You are experiencing active Atopic Dermatitis symptoms, such as: itchiness, irritated skin, redness, etc.
There are other eligibility requirements. A final decision on whether this research study might be suitable for you will be made after you speak with the study doctor at the research site. The study doctor will explain the benefits and risks of participation in this research study.
If you are eligible and enroll, you will receive study medication (or placebo), study visits and any necessary medical tests at no cost to you while you are in the study.
Atopic dermatitis is one of the most common type of eczema, affecting more than 9.6 million children and about 16.5 million adults in the United States. If you are an adult and have this condition, you might quality for this research study! Click Here to see if you qualify!